Sheet 1 of 1	
--------------	--

FORM PT	0-144	U.S. DE	PARTMENT	OF COMMERCE	TATTY DOOR	TT NO.	SERIAL				
	PATENT AND TRADEMARK OFFICE					ATTY. DOCKET NO.: IN01159K					
INI	INFORMATION DISCLOSURE STATEMENT				APPLICANT:	09/908,955					
ļ	BY APPLICANT					SAKSENA, et al					
	(Use several sheets if necessary)				FILING DATE	GROUP: TBA					
<b> </b>					07/19/2001						
+EVA 141115	<del>:_1 —</del>		U.S. P	PATENT DOCUM	<b>MENTS</b>						
*EXAMINE	R	DOCUMENT	DATE	NAM		CLASS	SUB-	FILING			
IIVITIAL	AA	NUMBER	<del></del>					APPRO			
	AB	<del> </del>	<del> </del>	<del> </del>					1 / (// / /		
	AC	<del></del>	<del> </del>	<del> </del>							
<del></del>			<u> </u>						<del></del>		
		F	-OREIGN	PATENT DOC	UMENTS	-					
	}	DOCOMENT	DATE	COUNTRY		CLASS	SUB-	TRANSI	ATION		
202	1	NUMBER					CLASS	YES	NO		
RBM	AD		10/11/01	WIPO		<del></del>		123	INO		
R.C.	AE	WO 01 40262	06/07/01	WIPO		+==			<del>                                      </del>		
PR	AF	WO 00 52032	09/08/00	WIPO		TRE			<del>                                     </del>		
REM	AG	WO 99 07734	02/18/99	WIPO			CEN		<del> </del>		
PB	AH	WO 98 17679	04/30/98	WIPO		+ 111		Same March	<del> </del>		
<del> </del>	AI					+	2 3 2	ากว			
<b> </b>	AJ					TO 10-		,02			
<b></b>	AK					HEUH CEN	VIER 160	10/0000			
<b> </b>	AJ					+	<u>, -11 1011</u>	WZ900			
<u> </u>	AK					++					
						<del> </del>	+				
u.	OTI	HER DOCUMENT	S (Includ	ing Author Title	Data Dart	<u> </u>					
- 2 0	AL	WEI HAN, et al. "alph	na-Ketoami	des alpha katanata	Date, Peni	inent Paç	ges, Etc	<u>:.)                                    </u>			
SEL,		inhibitors", BIOORGA	MENTS (Including Author, Title, Date, Pertinent Pages, Etc.) al, "alpha-Ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease IOORGANIC & MEDICINAL CHEMISTRY LETTERS, Vol. 10, No. 8, (2000), pp. 711-								
	AM	LLINAS-BRUNET MC	ONTSE, et	al. "Studies on the c	r-terminal of h	avanantida	- ! l- !L- !A				
262	. ,	LLINAS-BRUNET MONTSE, et al, "Studies on the c-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, Vol. 8, No. 19, (1998), pp. 2719-2724									
		No. 19, (1998), pp. 27	<u>/19-2724.</u>		WEDION WAL	JIILIVIIGIT	KY LEIIC	=KS, VC	ઝા. <mark>૪</mark> ,		
	AN										
	AO										
	AP										
	AQ						<del></del>				
EXAMINER				DATE CON	NSIDERED						
87	4	B. Mac	ب	1		>					
*EXAMNE		tial if mafaman and it		8	24-03	>					
through cita	X. ππ ition if	tial if reference considernot in conformance ar	ered, wheth	ier or not citation is	in conforman	ce with MP	EP 609;	Draw lir	ne		
applicant.	tion, i,	not in conformance ar	ia not cons	ildered. Include cor	by of this form	with next	communi	cation to			

	6	PEVC									
		JAN 0 3 2002 - E					Sheet _	<u>1</u> of	_1_		
FORM PTO	)-\@	U.S. DEI	PARTMENT	OF COMMERCE	ATTY. DOCK	ET NO.:	SERIAL	NO.:			
INFORMATION DISCLOSURE STATEMENT					IN01159K APPLICANT:	09/908					
BY APPLICANT  (Use several sheets if necessary)				VI EIVIEIVI	SAKSENA, et al			· · · · · · · · · · · · · · · · · · ·			
				ary)	FILING DATE:	GROUP		AN	8		
					July 19, 2001		To Be A	<u>'''</u>	卭		
*EXAMINER		DOCUMENT	DATE	ATENT DOCUM		CLAGO	1 0110	<u> </u>	15.3		
INITIAL		NUMBER				CLASS	SUB-	FILING APPRO	DATE		
per	AA	U.S. 5,712,145						AT THE	TNAT		
	AB							25			
<u> </u>		F	OREIGN	PATENT DOC	UMENTS					$\neg$	
		DOCUMENT	DATE	COUNTRY		CLASS	SUB-	TRANS	LATIO	딝	
000	1	NUMBER					CLASS	YES	NO	$\exists$	
26m	AC AD	WO 89/04669								$\dashv$	
060	AE	WO 98/17679 WO 98/22496								7	
RN	AF	WO 98/22496 WO 98/07734									
CH	AG	WO 00/09558									
240	AH	WO 00/09543				,					
Ver	Al	EP 381 216									
XX	AJ	2. 001210									
^ ^ =	AK					<del>   </del>			ļ	_	
	OT	HED DOCUMENT	C //: /:	A (1		<u> </u>				_	
04	AL	HER DOCUMENTS	S (Includii	ng Author, Title	<u>, Date, Perti</u>	nent Pa	ges, Etc	c.)		1	
	AM	Pizzi, (1994) <i>Proc. Na</i> Failla (1996) <i>folding &amp;</i>	au. Acaa. Si	CI(USA) 91:888-89	02	<u> </u>				7	
<del>- 77 or ∧</del>	AN	Kollykhalov (1994) <i>J.</i>	Virol 69:75	35-42				<u></u>			
	AO	Komoda (1994) <i>J. Vir</i>	virui. 66.73	7257						]	
	AP	Landro (1997) Bioche	m 36:9340	-7337						]	
-	AQ	Ingallinella (1998) Bio	chem 37:89	9040 906-891 <i>4</i>						_	
	AR	Llinas-Brunet (1998)	Bioora, Med	L. Chem. Lett. 8:17	13 1719					4	
RBM	AS	Martin (1998) Biocher	n 37:11459	-11468	10-17-10		<u> </u>			╣.	
	AT	Dimasi (1997) J. Virol	71:7461-7	469						4	
Stw.		Martin (1997) Protein	Eng. 10:607	7-614						1	
25h	AV	Elzouki (1997) J. Hep	at. 27:42-48	3						1	
	AW	Bio World Today 9(21	7): 4 (Nove	mber 10, 1998)						1	
- 4 1	AX AV	Berenguer (1998) Pro	c. Assoc. A	m. Physicians 110	(2): 98-112						
2	AY   AZ	Hoofnagle (1997) Nev	v <u>⊏ngland</u> J	ournal Med. 336:3	47					1	
	3A	Zhang (199) Analytica Sali (1998) Riochemia	tru 2200 0 1	try 270:268-275						1	
	3B	Sali (1998) Biochemis	opt Protoin	01 Dec 540 500						1	
	3C	Barlos (1991) <i>Int. J. P</i> Holmberg (1979) <i>Acta</i>	Chem Soo	rtes 513-520		·				]	
E	3D	Agrawal(1999) Henato	ology Supple	ment to Vol 20 "F	Noveles and		<u> </u>			]	
ex		Agrawal(1999) Hepato C Virus Serine Proteas	se Cell-base	ed Trans-Cleavage	evelopment ar	na Charac	terization	of Hepa	atitis		
	2E .	Hugnes (1992) Org. R	eactions 42	:335	o riosay						
	3F	Heck (1989) <i>Org. Rea</i>	ctions 27:34	15-390				<del></del>			
een B	G	Han, (2000) <i>Bioorgani</i> e	c & Medicin	al Chemistry Lette	ers 10 "a-Ketoa	mides ~	Ketoosto	re and			
		Han, (2000) Bioorganic & Medicinal Chemistry Letters 10 "α-Ketoamides, α-Ketoesters and α-Kiketones as HCV NS3 Protease Inhibitors" pp. 711-713.  Marchetti(1999) Synlett, Vol. S1, "Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease", pp. 1000, 1000									
RON B	in H	Marchetti(1999) <i>Synlett</i>	. Vol. S1. "	Synthesis of Two	Novel Cyclic B	iphenvl Ft	her Analo	ogs of a			
XAMINER		Inhibitor of HCV NS3 F	Protease", p	p 1000-1002.			raidic	-go oi ai	'		
				DATE CON	NSIDERED						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

8-24-03